Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Eitemau Tebyg

• Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
  gan: Kavanaugh, Arthur, et al.
  Cyhoeddwyd: (2018)
• Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
  gan: Kavanaugh, Arthur, et al.
  Cyhoeddwyd: (2013)
• Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
  gan: Burmester, Gerd R, et al.
  Cyhoeddwyd: (2017)
• Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
  gan: Keystone, Edward C, et al.
  Cyhoeddwyd: (2018)
• Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
  gan: Keystone, Edward C, et al.
  Cyhoeddwyd: (2017)